Randel Smith, MD
Interventional Cardiology · Dickson, TNNPI 1639288293
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $814, 2.0 times the $403 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in TN, where the typical reported total is $7,646.
Across 121 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$671
- Medtronic$609
- Abiomed$379
- Boston Scientific$281
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$166
- Philips North America LLC$158
- plus $874 from 14 others
Across 58 payments — averaging $2651.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$82K
- Livanova USA, Inc.$66K
- Tryton Medical, Inc.$5K
- Medtronic$1K
What the payments were for
- Food & beverage$3,06298%
- Gifts$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 36 | $671 |
| Medtronic(2 entities) | 10 | $609 |
| Abiomed | 29 | $379 |
| Boston Scientific | 7 | $281 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $166 |
| Philips North America LLC | 5 | $158 |
| Lexicon Pharmaceuticals, Inc. | 4 | $137 |
| Abbott | 3 | $117 |
| Chiesi USA, Inc. | 4 | $116 |
| Shockwave Medical, Inc | 1 | $111 |
| Scpharmaceuticals Inc. | 1 | $92 |
| Actelion Pharmaceuticals US, Inc. | 1 | $67 |
| Bayer | 2 | $50 |
| Pfizer | 3 | $42 |
| Boehringer Ingelheim | 2 | $31 |
| GE HealthCare | 1 | $29 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,137 in reported general payments places this provider in the 20th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $36,721 |
| FarxigaDapagliflozin Propanediol | 33 | $27,897 |
| EntrestoSacubitril/Valsartan | 11 | $7,949 |
| BrilintaTicagrelor | 14 | $7,502 |
| Metoprolol Succinate | 100 | $953 |
| Ezetimibe | 52 | $870 |
| Atorvastatin Calcium | 109 | $824 |
| Rosuvastatin Calcium | 43 | $653 |
| ClopidogrelClopidogrel Bisulfate | 81 | $567 |
| Amiodarone Hcl | 19 | $435 |
| Potassium Chloride | 31 | $397 |
| Losartan Potassium | 49 | $301 |
| Nebivolol Hcl | 14 | $299 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $259 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $36,72146 claims |
| NovartisEntresto | $671 | $7,94911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Dickson
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
- Joseph WeinsteinMemphis$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.